



Uscom

ASX MEDIA RELEASE

Mr Meng Joins Uscom Board

SYDNEY, Australia, Monday 16th December 2019: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today announced the appointment of Mr Meng Xianhui to the Uscom Limited Board. Mr Meng joins Christian Bernecker and Brett Crowley as non-executive Directors of the Company. Mr Meng joined the Uscom register in December 2017 with a 10% investment in the company, and has since increased his holdings incrementally to more than 21% over the last 18 months.

Mr Meng is an experienced private and international value investor with investments across multiple sectors and countries, and has qualifications in economics, engineering management and business administration. Mr Meng has 10 years experience as a China government departmental head (1987 to 1997), and 20 years experience as the Executive Manager and Executive Director of a major Listed Chinese Pharma from 2006 to 2017 specialising in sales and distribution, and will bring both his international corporate and strategic skills to the Uscom Board.

In the last 18 months Uscom has appointed a Director of China operations, Ms Teresa Guo, who has established Uscom China in Beijing, received business and finance registrations, established device import approvals and pathways, prepared and monitored multiple NMPA submissions, implemented a new distributor and dealer sales model and network, received Type II medical device sales approval, has received 8 IP approvals with more in review, and developed a national clinical and technical support model.

Uscom China's strategy is to expand and consolidate its distribution activities into China as Uscom's new products receive NMPA approval, expected during FY 2020. There are now approximately 30,000 Chinese hospitals across the 31 Chinese provinces providing an increasingly sophisticated health care service to the approximately 1.4B people of China.

Executive Chairman of Uscom, Professor Rob Phillips said *"We have invested in valuable infrastructure in China, and Mr Meng's Board appointment is an incremental strategic step for Uscom as we scale up in preparation for our NMPA approvals. Direct connection into the evolving world of Chinese business and bureaucracy brings a strategic insight unavailable to non-Chinese, and consolidates our long term China strategy. Mr Meng is experienced in Chinese medical markets, and his increasing holding in the company reflects his belief in the future of Uscom; he is a believer, supporter, investor, and now a Board member of Uscom."*

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases. The USCOM 1A provides vital guidance for optimising management of sepsis and the administration of fluid, inotropes and vasoactive therapies in critical care monitoring. The BP+ SpiroSonic devices improve diagnosis and management of hypertension, heart failure, asthma, COPD and sleep disorders in the clinical and home care environments.



Uscom

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary **SpiroReporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary